biostudies-literatureUnknown13Al Jurdi AMassachusetts General Hospital<h4>Introduction</h4>Studies have shown reduced antiviral responses in kidney transplant recipients (KTRs) following SARS-CoV-2 mRNA vaccination, but data on post-vaccination alloimmune responses and antiviral responses against the Delta (B.1.617.2) variant are limited.<h4>Materials and methods</h4>To address this issue, we conducted a prospective, multi-center study of 58 adult KTRs receiving mRNA-BNT162b2 or mRNA-1273 vaccines. We used multiple complementary non-invasive biomarkers for rejection monitoring including serum creatinine, proteinuria, donor-derived cell-free DNA, peripheral blood gene expression profile (PBGEP), urinary <i>CXCL9</i> mRNA and <i>de novo</i> donor-specific antibodies (DSA). Secondary outcomes included development of anti-viral immune responses against the wild-Frontiers in immunology838985https://www.ebi.ac.uk/biostudies/studies/S-EPMC8913529biostudies-literatureNon-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.PMC8913529Alghamdi ABohan BSolhjou ZPattanayak VMohammed MTKotton CNAl Jurdi AAzzi JRHullekes FEEfe OPatel PRiella LVBorges TJCravedi PGassen RBChoi JYLape ITRosales IfalseNon-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.<h4>Introduction</h4>Studies have shown reduced antiviral responses in kidney transplant recipients (KTRs) following SARS-CoV-2 mRNA vaccination, but data on post-vaccination alloimmune responses and antiviral responses against the Delta (B.1.617.2) variant are limited.<h4>Materials and methods</h4>To address this issue, we conducted a prospective, multi-center study of 58 adult KTRs receiving mRNA-BNT162b2 or mRNA-1273 vaccines. We used multiple complementary non-invasive biomarkers for rejection monitoring including serum creatinine, proteinuria, donor-derived cell-free DNA, peripheral blood gene expression profile (PBGEP), urinary <i>CXCL9</i> mRNA and <i>de novo</i> donor-specific antibodies (DSA). Secondary outcomes included development of anti-viral immune responses against the wild-2022-01-01T00:00:00Z20222025-04-04T08:53:46.53Z2025-04-04T08:53:46.53ZS-EPMC89135293528101110.3389/fimmu.2022.838985